Skip to main content
SpringerLink
Log in

Gene Therapy for Inherited Metabolic Diseases

  • Chapter
  • First Online:
Nutrition Management of Inherited Metabolic Diseases

  • 1054 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455–64.

    Article  CAS  PubMed  Google Scholar 

  2. Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359:6372.

    Article  CAS  Google Scholar 

  3. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2):148–58.

    Article  CAS  PubMed  Google Scholar 

  4. Naldini L. Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. EMBO Mol Med. 2019;11(3):e9958.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351–60.

    Article  CAS  PubMed  Google Scholar 

  6. Bushman FD. Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones. Mol Ther. 2020;28(2):352–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Pasqauli M, Longo N. Newborn screening and inborn errors of metabolism. In: Rifai N, Horvath A, Wittwer C, editors. Fundamentals of clinical chemistry 8th edition. 8th ed. USA: Elsevier; 2020. p. 882–97.

    Google Scholar 

  8. Yuzyuk T, Viau K, Andrews A, Pasquali M, Longo N. Biochemical changes and clinical outcomes in 34 patients with classic galactosemia. J Inherit Metab Dis. 2018;41(2):197–208.

    Article  CAS  PubMed  Google Scholar 

  9. Jameson E, Remmington T. Dietary interventions for phenylketonuria. Cochrane Database Syst Rev. 2020;7:CD001304.

    PubMed  Google Scholar 

  10. Pearl PL. Amenable treatable severe pediatric epilepsies. Semin Pediatr Neurol. 2016;23(2):158–66.

    Article  PubMed  Google Scholar 

  11. Rahman S. Emerging aspects of treatment in mitochondrial disorders. J Inherit Metab Dis. 2015;38(4):641–53.

    Article  CAS  PubMed  Google Scholar 

  12. Manzoni F, Salvatici E, Burlina A, Andrews A, Pasquali M, Longo N. Retrospective analysis of 19 patients with 6-pyruvoyl tetrahydropterin synthase deficiency: prolactin levels inversely correlate with growth. Mol Genet Metab. 2020;131(4):380–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Trefz FK, Burton BK, Longo N, Casanova MM, Gruskin DJ, Dorenbaum A, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. 2009;154(5):700–7.

    Article  CAS  PubMed  Google Scholar 

  14. Clayton PT. The effectiveness of correcting abnormal metabolic profiles. J Inherit Metab Dis. 2020;43(1):2–13.

    Article  CAS  PubMed  Google Scholar 

  15. Koto Y, Ueki S, Yamakawa M, Sakai N. Experiences of patients with lysosomal storage disorders treated with enzyme replacement therapy: a qualitative systematic review protocol. JBI Evid Synth. 2020;19(3):702–8.

    Article  Google Scholar 

  16. Sheth J, Nair A. Treatment for lysosomal storage disorders. Curr Pharm Des. 2020;26(40):5110–8.

    Article  CAS  PubMed  Google Scholar 

  17. Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549–58.

    Article  PubMed  Google Scholar 

  18. Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915–23.

    Article  CAS  PubMed  Google Scholar 

  19. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017–26.

    Article  CAS  PubMed  Google Scholar 

  20. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185–93.

    Article  CAS  PubMed  Google Scholar 

  21. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296(5577):2410–3.

    Article  CAS  PubMed  Google Scholar 

  22. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415–9.

    Article  CAS  PubMed  Google Scholar 

  23. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198–204.

    Article  CAS  PubMed  Google Scholar 

  24. Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et al. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):227ra33.

    Article  PubMed  CAS  Google Scholar 

  25. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300(5626):1749–51.

    Article  CAS  PubMed  Google Scholar 

  26. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341(6148):1233151.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014;371(15):1407–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447–58.

    Article  CAS  PubMed  Google Scholar 

  29. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002;99(8):2670–6.

    Article  CAS  PubMed  Google Scholar 

  30. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342–7.

    Article  CAS  PubMed  Google Scholar 

  31. Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond HE, Leiby J, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39(1):47–55.

    Article  CAS  PubMed  Google Scholar 

  32. French RA, Samelson-Jones BJ, Niemeyer GP, Lothrop CD Jr, Merricks EP, Nichols TC, et al. Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Adv. 2018;2(5):505–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388(10045):661–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Hwu WL, Muramatsu S, Tseng SH, Tzen KY, Lee NC, Chien YH, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med. 2012;4(134):134ra61.

    Article  PubMed  CAS  Google Scholar 

  36. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–22.

    Article  CAS  PubMed  Google Scholar 

  37. Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, et al. Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther. 2002;13(3):345–54.

    Article  CAS  PubMed  Google Scholar 

  38. Sung YK, Kim SW. Recent advances in the development of bio-reducible polymers for efficient cancer gene delivery systems. Cancer Med J. 2019;2(1):6–13.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm. 1999;7(3–4):189–98.

    Article  PubMed  Google Scholar 

  41. Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35(3):689–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Brannagan TH, Wang AK, Coelho T, Waddington Cruz M, Polydefkis MJ, Dyck PJ, et al. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol. 2020;27(8):1374–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Dowling JJ. Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat Rev Neurol. 2016;12(12):675–6.

    Article  CAS  PubMed  Google Scholar 

  44. Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94(21):e2270–e82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. de Holanda MR, Jorge Polido G, Ciro M, Jorge Fontoura Solla D, Conti Reed U, Zanoteli E. Clinical outcomes in patients with spinal muscular atrophy type 1 treated with nusinersen. J Neuromuscul Dis. 2021;8(2):217–24.

    Article  Google Scholar 

  46. Yuan YR, Pei Y, Chen HY, Tuschl T, Patel DJ. A potential protein-RNA recognition event along the RISC-loading pathway from the structure of A. aeolicus Argonaute with externally bound siRNA. Structure. 2006;14(10):1557–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. de Paula Brandao PR, Titze-de-Almeida SS, Titze-de-Almeida R. Leading RNA interference therapeutics part 2: silencing delta-aminolevulinic acid synthase 1, with a focus on givosiran. Mol Diagn Ther. 2020;24(1):61–8.

    Article  PubMed  CAS  Google Scholar 

  48. Milani P, Mussinelli R, Perlini S, Palladini G, Obici L. An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis. Expert Opin Pharmacother. 2019;20(18):2223–8.

    Article  CAS  PubMed  Google Scholar 

  49. Schneller JL, Lee CM, Bao G, Venditti CP. Genome editing for inborn errors of metabolism: advancing towards the clinic. BMC Med. 2017;15(1):43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Richards DY, Winn SR, Dudley S, Nygaard S, Mighell TL, Grompe M, et al. AAV-mediated CRISPR/Cas9 gene editing in murine phenylketonuria. Mol Ther Methods Clin Dev. 2020;17:234–45.

    Article  CAS  PubMed  Google Scholar 

  51. Callaway E. COVID vaccine excitement builds as Moderna reports third positive result. Nature. 2020;587(7834):337–8.

    Article  CAS  PubMed  Google Scholar 

  52. Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X, et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020;30(10):936–9.

    Article  CAS  PubMed  Google Scholar 

  53. Mahase E. Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy. BMJ. 2020;371:m4709.

    Article  PubMed  Google Scholar 

  54. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.

    Article  CAS  PubMed  Google Scholar 

  55. An D, Frassetto A, Jacquinet E, Eybye M, Milano J, DeAntonis C, et al. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. EBioMedicine. 2019;45:519–28.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Balakrishnan B, An D, Nguyen V, DeAntonis C, Martini PGV, Lai K. Novel mRNA-based therapy reduces toxic galactose metabolites and overcomes galactose sensitivity in a mouse model of classic galactosemia. Mol Ther. 2020;28(1):304–12.

    Article  CAS  PubMed  Google Scholar 

  57. Truong B, Allegri G, Liu XB, Burke KE, Zhu X, Cederbaum SD, et al. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. Proc Natl Acad Sci U S A. 2019;116(42):21150–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Cao J, An D, Galduroz M, Zhuo J, Liang S, Eybye M, et al. mRNA therapy improves metabolic and behavioral abnormalities in a murine model of citrin deficiency. Mol Ther. 2019;27(7):1242–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Jiang L, Park JS, Yin L, Laureano R, Jacquinet E, Yang J, et al. Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat Commun. 2020;11(1):5339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Jiang L, Berraondo P, Jerico D, Guey LT, Sampedro A, Frassetto A, et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med. 2018;24(12):1899–909.

    Article  CAS  PubMed  Google Scholar 

  61. Zhu X, Yin L, Theisen M, Zhuo J, Siddiqui S, Levy B, et al. Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates. Am J Hum Genet. 2019;104(4):625–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Tang X, Zhang S, Fu R, Zhang L, Huang K, Peng H, et al. Therapeutic prospects of mRNA-based gene therapy for glioblastoma. Front Oncol. 2019;9:1208.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Kauffman KJ, Mir FF, Jhunjhunwala S, Kaczmarek JC, Hurtado JE, Yang JH, et al. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. Biomaterials. 2016;109:78–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Weissman D, Kariko K. mRNA: fulfilling the promise of gene therapy. Mol Ther. 2015;23(9):1416–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Kaczmarek JC, Patel AK, Kauffman KJ, Fenton OS, Webber MJ, Heartlein MW, et al. Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew Chem Int Ed Engl. 2016;55(44):13808–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Moderna’s Clinical Trials 2021. Available from: https://www.modernatx.com/pipeline/modernas-mrna-clinical-trials-cmv-mma-zika-several-types-cancer-and-other-diseases.

  68. Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther. 2018;26(6):1509–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. An D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21(12):3548–58.

    Article  CAS  PubMed  Google Scholar 

  70. Wierzbicki AS, Viljoen A. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opin Biol Ther. 2013;13(1):7–10.

    Article  CAS  PubMed  Google Scholar 

  71. Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–93.

    Article  CAS  PubMed  Google Scholar 

  72. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol. 2010;11(6):457–60.

    Article  CAS  PubMed  Google Scholar 

  73. Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, et al. Gene therapy in patients with transfusion-dependent beta-thalassemia. N Engl J Med. 2018;378(16):1479–93.

    Article  CAS  PubMed  Google Scholar 

  74. Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, Smith JB, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev. 2013;24(2):55–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol. 2019;100:3–11.

    Article  PubMed  Google Scholar 

  76. Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet. 2016;17(5):300–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015;6(5):363–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Friedmann T, Jonlin EC, King NMP, Torbett BE, Wivel NA, Kaneda Y, et al. ASGCT and JSGT joint position statement on human genomic editing. Mol Ther. 2015;23(8):1282.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Human genome editing: science, ethics, and governance. Washington, DC; 2017.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Genetics, University of Utah School of Medicine, University of Utah Hospital, Salt Lake City, UT, USA

    Nicola Longo

  2. Division of Pediatric Genetics, University of Utah School of Medicine, Salt Lake City, UT, USA

    Kent Lai

Authors
  1. Nicola Longo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kent Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Longo .

Editor information

Editors and Affiliations

  1. Children’s Hospital Colorado, University of Colorado Hospital, Aurora, CO, USA

    Laurie E. Bernstein

  2. Met Ed Co, Boulder, CO, USA

    Fran Rohr

  3. Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA

    Sandy van Calcar

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Longo, N., Lai, K. (2022). Gene Therapy for Inherited Metabolic Diseases. In: Bernstein, L.E., Rohr, F., van Calcar, S. (eds) Nutrition Management of Inherited Metabolic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-94510-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-94510-7_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-94509-1

  • Online ISBN: 978-3-030-94510-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation